APVO (Aptevo Therapeutics Inc.) stock: $1.22, $3.3M market cap, $9.8M cash, -$6.5M EV, $10.6M fully diluted market cap. Next expected readout: Oct-27. Lead program: APVO436 (Acute Myeloid Leukemia (AML)), Phase 1. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead clinical blood cancer candidate; bispecific ADAPTIR targeting CD123 x CD3. FDA orphan drug designation for AML (Nov 2019). Phase 1a monotherapy dose escalation and Phase 1b dose expansion completed; Phase 1b/2 RAINIER trial in frontline AML (combination with venetoclax + azacitidine) ongoing with dose optimization for RP2D selection.
ALG.APV-527
Phase 1 · ActiveModality: bispecific antibody
Target 4-1BB (CD137) x 5T4
Partnerships Alligator Bioscience AB: collaboration and option agreement (July 20, 2017); 50/50 cost sharing; jointly owned collaboration IP with opt-out points
Indications
Solid tumors(Phase 1)
Status note Lead solid tumor candidate; bispecific ADAPTIR targeting 4-1BB (CD137) x 5T4. Phase 1 dose escalation trial completed; Aptevo and Alligator evaluating next steps for the dose expansion trial.
APVO603
Preclinical · ActiveModality: bispecific antibody
Target 4-1BB (CD137) x OX40 (CD134)
Indications
Solid tumors(Preclinical)
Status note Preclinical bispecific ADAPTIR candidate targeting 4-1BB (CD137) x OX40 (CD134) (targets per 10-K fallback).
APVO711
Preclinical · ActiveModality: bispecific antibody
Target PD-L1 x CD40
Indications
Cancer(Preclinical)
Status note Preclinical bispecific ADAPTIR candidate targeting PD-L1 x CD40 (targets per 10-K fallback).
Partnerships Niowave: 50/50 collaboration agreement (May 25, 2026) to develop up to three radiopharmaceutical oncology programs combining Aptevo proprietary molecules with Niowave radioisotopes; supply agreement plus Niowave equity investment
Indications
Cancer(Discovery)
Status note Up to three radiopharmaceutical oncology programs; candidate names not disclosed in filing.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.